Search results for "WORKING GROUP"

showing 10 items of 58 documents

Developing common protocols to measure tundra herbivory across spatial scales

2021

Understanding and predicting large-scale ecological responses to global environmental change requires comparative studies across geographic scales with coordinated efforts and standardized methodologies. We designed, applied and assessed standardized protocols to measure tundra herbivory at three spatial scales: plot, site (habitat), and study area (landscape). The plot and site-level protocols were tested in the field during summers 2014-2015 at eleven sites, nine of them comprising warming experimental plots included in the International Tundra Experiment (ITEX). The study area protocols were assessed during 2014-2018 at 24 study areas across the Arctic. Our protocols provide comparable a…

0106 biological sciencestundra010504 meteorology & atmospheric sciencesEnvironmental changehabitat01 natural sciencesEcological monitoringITEXHerbivory NetworkvertebrateInvertebrateGeneral Environmental ScienceherbivoryEnvironmental resource managementenvironmental changeInternational Tundra ExperimentPeer reviewcommunitiesCOMMUNITYSUMMERGeneral Agricultural and Biological SciencessamplingwarmingconstraintMeasure (physics)herbivoreecological monitoring010603 evolutionary biologyENVIRONMENTAL-CHANGEscaleVDP::Mathematics and natural science: 400::Zoology and botany: 480arcticLife ScienceInternational Tundra Experiment (ITEX)Interactions Working Group (IWG)0105 earth and related environmental sciencesecosystemspatial scaleHerbivorebusiness.industryBusiness Manager projecten Midden-Noordglobal environmental changeCONSTRAINTSarealandscapeTundraspatialstandardized protocolGeneral Earth and Planetary SciencesEnvironmental sciencebusinessBusiness Manager projects Mid-NorthVDP::Matematikk og Naturvitenskap: 400::Zoologiske og botaniske fag: 480ecosystem responsesRESPONSESArctic Science
researchProduct

Proceedings of the 2nd BEAT-PCD conference and 3rd PCD training school: part 1

2018

Primary ciliary dyskinesia (PCD) is a rare heterogenous condition that causes progressive suppurative lung disease, chronic rhinosinusitis, chronic otitis media, infertility and abnormal situs. ‘Better Experimental Approaches to Treat Primary Ciliary Dyskinesia’ (BEAT-PCD) is a network of scientists and clinicians coordinating research from basic science through to clinical care with the intention of developing treatments and diagnostics that lead to improved long-term outcomes for patients. BEAT-PCD activities are supported by EU funded COST Action (BM1407). The second BEAT-PCD conference, and third PCD training school were held jointly in April 2017 in Valencia, Spain. Presentations and w…

0301 basic medicineChronic rhinosinusitiseducationMEDLINElcsh:Medicine610 Medicine & healthMeeting ReportGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineMultidisciplinary approach360 Social problems & social servicesmedicineotorhinolaryngologic diseasesCost actionlcsh:Science610 Medicine & healthPrimary ciliary dyskinesiaMedical educationbusiness.industrylcsh:RGeneral Medicinemedicine.diseaseClinical trial030104 developmental biology030228 respiratory systemLung diseaseMalaltieslcsh:QWorking groupbusiness360 Social problems & social services
researchProduct

Current state of genomic policies in healthcare among EU member states: results of a survey of chief medical officers

2016

Abstract Background A need for a governance of genomics in healthcare among European Union (EU) countries arose during an international meeting of experts on public health genomics (PHG). We have conducted a survey on existing national genomic policies in healthcare among Chief Medical Officers (CMOs) of the 28 EU member states, plus Norway. Methods A questionnaire was sent to CMOs after a meeting on the policy implications of PHG held during the Italian presidency of the Council of EU in 2014. The survey was closed in November 2015. Results CMOs response rate was 65.5% (19/29). Twelve (63.2%) reported that their countries had a policy for genomics in healthcare in place, and 15 (78.9%) rep…

0301 basic medicineEconomic growthPresidencyHealth Personnelsurvey.Harmonization030105 genetics & hereditySettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesEnvironmental healthHealth careHumansmedia_common.cataloged_instanceMedicineEuropean Union030212 general & internal medicineEuropean unionSurveySettore MED/42 - IGIENE GENERALE E APPLICATAmedia_common...Public Health; genomics and health care; Public Health Genomics; policy; survey.Public health genomicsNorwaybusiness.industryCorporate governanceHealthcarePublic Health Environmental and Occupational HealthHealth technologyGenomicsgenetic screeningPublic health genomicMiscellaneous3. Good healthpublic health medicinePublic Healthgenomics and health careWorking groupbusinessDelivery of Health Carepolicy
researchProduct

Recent Progress and Recommendations on Celiac Disease From the Working Group on Prolamin Analysis and Toxicity

2020

Celiac disease (CD) affects a growing number of individuals worldwide. To elucidate the causes for this increase, future multidisciplinary collaboration is key to understanding the interactions between immunoreactive components in gluten-containing cereals and the human gastrointestinal tract and immune system and to devise strategies for CD prevention and treatment beyond the gluten-free diet. During the last meetings, the Working Group on Prolamin Analysis and Toxicity (Prolamin Working Group, PWG) discussed recent progress in the field together with key stakeholders from celiac disease societies, academia, industry and regulatory bodies. Based on the current state of knowledge, this pers…

0301 basic medicineEndocrinology Diabetes and MetabolismBiologíaReviewDisease//purl.org/becyt/ford/1 [https]0302 clinical medicinegluten-free dietwheatMedicineCeliac disease2. Zero hungerchemistry.chemical_classificationNutrition and DieteticsbiologyMultidisciplinary CollaborationGLUTEN FREE DIETProlamin working group3. Good healthCompliance Monitoring[SDV.TOX]Life Sciences [q-bio]/ToxicologyProlamin Working GroupWheatGluten-free dietlcsh:Nutrition. Foods and food supplyLife sciences; biologylcsh:TX341-641030209 endocrinology & metabolism03 medical and health sciencesRyeddc:570Environmental healthBarleyProlamin//purl.org/becyt/ford/1.6 [https]Nutrition030109 nutrition & dieteticsbusiness.industrybarleynutritional and metabolic diseasesGlutendigestive system diseasesryePlant BreedingchemistryglutenCiencias Médicasbiology.proteinbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyceliac diseaseGlutenFood Science
researchProduct

Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders

2018

International audience; C-reactive protein (CRP) is a sensitive biomarker of chronic low-grade inflammation and is associated with multiple complex diseases. The genetic determinants of chronic inflammation remain largely unknown, and the causal role of CRP in several clinical outcomes is debated. We performed two genome-wide association studies (GWASs), on HapMap and 1000 Genomes imputed data, of circulating amounts of CRP by using data from 88 studies comprising 204,402 European individuals. Additionally, we performed in silico functional analyses and Mendelian randomization analyses with several clinical outcomes. The GWAS meta-analyses of CRP revealed 58 distinct genetic loci (p < 5 × 1…

0301 basic medicineMaleNetherlands Twin Register (NTR)Bipolar DisorderLD SCORE REGRESSION[SDV]Life Sciences [q-bio]Genome-wide association study[SDV.GEN] Life Sciences [q-bio]/GeneticsBody Mass Indexinflammatory disorder80 and overWIDE ASSOCIATIONEPIDEMIOLOGYta318International HapMap ProjectChildGenetics (clinical)2. Zero hungerGeneticsGenetics & HeredityAged 80 and over[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyC-reactive proteingenome-wide association studyinflammationMendelian randomizationinflammatory disordersDEPICTcoronary artery diseaseschizophreniasystem biologysystem biologyDEPICTMendelian Randomization Analysis11 Medical And Health SciencesMiddle AgedC-reactive protein; coronary artery disease; DEPICT; genome-wide association study; inflammation; inflammatory disorders; Mendelian randomization; schizophrenia; system biology; Adolescent; Adult; Aged; Aged 80 and over; Biomarkers; Bipolar Disorder; Body Mass Index; C-Reactive Protein; Child; Female; Genetic Loci; Genome-Wide Association Study; Humans; Inflammation; Liver; Male; Mendelian Randomization Analysis; Metabolic Networks and Pathways; Middle Aged; Schizophrenia; Young Adult3. Good health[SDV] Life Sciences [q-bio]LiverMedical geneticsBiomarker (medicine)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleinflammatory disordersLife Sciences & BiomedicineMetabolic Networks and Pathwayscoronary artery diseaseHumanAdultmedicine.medical_specialtyAdolescentCHARGE Inflammation Working GroupC-reactive protein ; DEPICT ; Mendelian randomization ; coronary artery disease ; genome-wide association study ; inflammation ; inflammatory disorders ; schizophrenia ; system biologyBiologyIMMUNITYta3111ArticleC-reactive protein03 medical and health sciencesYoung AdultSDG 3 - Good Health and Well-beingMendelian randomizationGeneticsmedicine/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_Mendelian randomizationHumansCORONARY-HEART-DISEASEMendelian Randomization Analysi1000 Genomes ProjectMETAANALYSISGenetic associationAged[SDV.GEN]Life Sciences [q-bio]/GeneticsScience & Technologygenome-wide association studyta1184Metabolic Networks and PathwayBiomarkerINSTRUMENTS06 Biological SciencesMendelian Randomization Analysisschizophrenia030104 developmental biologyGenetic LociinflammationC-reactive protein; DEPICT; Mendelian randomization; coronary artery disease; genome-wide association study; inflammation; inflammatory disorders; schizophrenia; system biology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBiomarkersLifeLines Cohort Study
researchProduct

Proteomics Standards Initiative: Fifteen Years of Progress and Future Work.

2017

Abstract: The Proteomics Standards Initiative (PSI) of the Human Proteome Organization (HUPO) has now been developing and promoting open community standards and software tools in the field of proteomics for 15 years. Under the guidance of the chair, co-chairs, and other leadership positions, the PSI working groups are tasked with the development and maintenance of community standards via special workshops and ongoing work. Among the existing, ratified standards, the PSI working groups continue to update PSI-MI XML, MITAB, mzML, mzIdentML, mzQuantML, mzTab, and the MIAPE (Minimum Information About a Proteomics Experiment) guidelines with the advance of new technologies and techniques. Furthe…

0301 basic medicineProteomicsprotein quantificationEmerging technologiesComputer sciencecomputer.internet_protocolGuidelines as Topiccomputer.software_genreBiochemistry03 medical and health sciencesprotein identificationHuman proteome projectHumansCommunity standardsquality controlDatabases ProteinBiologydatabasemass spectrometryComputer. Automation030102 biochemistry & molecular biologyApplication programming interfaceProteomics Standards InitiativeGeneral ChemistryReference StandardsData sciencemetabolomicsChemistry030104 developmental biologyPerspectivedata standardWeb servicebioinformatics softwareWorking groupcomputerXMLSoftwaremolecular interactionsJournal of proteome research
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

Statement of the Prolamin Working Group on the Determination of Gluten in Fermented Foods Containing Partially Hydrolyzed Gluten

2021

On August 12, 2020, the U.S. Food and Drug Administration (FDA) has finalized a rule related to gluten-free labeling for foods containing fermented, hydrolyzed ingredients. The FDA believes that there is no scientifically valid analytical method effective for determining gluten in fermented or hydrolyzed foods. In the absence of an analytical method, the FDA has decided to evaluate gluten-free claims on these foods based only on evidence that the food or ingredient used is gluten-free before fermentation or hydrolysis. For example, barley-based beers from which gluten is removed during brewing using special filtration, adsorption and/or enzymatic treatment are therefore excluded from bearin…

0301 basic medicineanalysifermented foodanalysisEndocrinology Diabetes and MetabolismIngredientProlaminFood scienceIngredient0302 clinical medicinehydrolysed beer[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceFermentation in food processingComputingMilieux_MISCELLANEOUS2. Zero hungerchemistry.chemical_classificationNutrition and DieteticsbiologyChemistryHydrolysisdigestive oral and skin physiologyfood and beveragesQuímicaChemistryFermentation in food processingProlamin Working Groupgluten-free foodpartially hydrolyzed glutenlcsh:Nutrition. Foods and food supplyLife sciences; biologyOpinioncompetitive ELISAlcsh:TX341-641030209 endocrinology & metabolismdigestive systemFood and drug administration03 medical and health sciencesHydrolysisddc:570ProlaminLC-MS/MSFood and drug administrationNutrition030109 nutrition & dieteticsbusiness.industrynutritional and metabolic diseasesBrewingGlutendigestive system diseasesPlant BreedingglutenFermentationbiology.proteinBrewingFermentation[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionceliac diseaseFrontiers in Nutrition
researchProduct

Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.

2015

BACKGROUND There is still uncertainty about what constitutes the best therapeutic practice in ulcerative colitis (UC). OBJECTIVE The purpose of the "UC Horizons Project" was to raise a series of questions regarding the management of UC to provide responses based on the best scientific evidence available. METHODS The 11 members of the scientific committee prepared draft answers to the 10 questions from available evidence after a literature search. A total of 48 Spanish gastroenterology specialists nationwide participated in the project. The national meeting discussed the 10 issues in working groups and reached consensus regarding the recommendations by anonymous, interactive vote following t…

0301 basic medicinemedicine.medical_specialtyConsensusAttitude of Health PersonnelAlternative medicineDelphi methodGastroenterologyScientific evidence03 medical and health sciences0302 clinical medicineInternal medicinePhysiciansSurveys and QuestionnairesmedicineImmunology and AllergyHumansDisease management (health)Thiopurine methyltransferasebiologybusiness.industryRemission InductionGastroenterologyDisease ManagementEvidence-based medicineDiscontinuation030104 developmental biologyFamily medicinePractice Guidelines as Topicbiology.protein030211 gastroenterology & hepatologyColitis UlcerativeWorking groupbusinessInflammatory bowel diseases
researchProduct

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome

2018

Abstract Aim Mucopolysaccharidosis type I is a lysosomal storage disorder that can result in significant disease burden, disability and premature death, if left untreated. The aim of this review was to elaborate on the diagnosis of mucopolysaccharidosis type I and the pros and cons of newborn screening. Methods An international working group was established to discuss ways to improve the early diagnosis of mucopolysaccharidosis type I. It consisted of 13 experts in paediatrics, rare diseases and inherited metabolic diseases from Europe and the Middle East. Results It is becoming increasingly clearer that the delay between symptom onset and clinical diagnosis is considerable for mucopolysacc…

0301 basic medicinemedicine.medical_specialtyHaematopoietic stem cell transplantLysosomal storage disorderMucopolysaccharidosis ILysosomal storage disordersReview ArticleDisease03 medical and health sciencesMucopolysaccharidosis type INeonatal Screening0302 clinical medicinemedicineHumansLaronidasePediatrics Perinatology and Child HealthIntensive care medicineReview ArticlesDisease burdenNewborn screeningbusiness.industryMucopolysaccharidosis type IInfant NewbornGeneral MedicineEnzyme replacement therapyInternational working group030104 developmental biologyEnzyme replacement therapyClinical diagnosisPediatrics Perinatology and Child Healthbusiness030217 neurology & neurosurgeryActa Paediatrica
researchProduct